tirzepatide surmount 5 In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Surmount-5 - Page 1 |
Pay in 4 interest-free payments of $7.42 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
![tirzepatide surmount 5 In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Surmount-5 - Page 1 |](https://www.bioworld.com/ext/resources/Stock-images/Drugs/Zepbound-vials.webp?height=488&t=1733348648&width=650)
![tirzepatide surmount 5 In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Surmount-5 - Page 1 |](https://www.truveta.com/wp-content/uploads/2024/12/GLP-1-study-validated.png)
![tirzepatide surmount 5 In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Surmount-5 - Page 1 |](https://pbs.twimg.com/media/Gq1XyZ_WwAAbdzC.png)
![tirzepatide surmount 5 In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Surmount-5 - Page 1 |](https://images.squarespace-cdn.com/content/v1/675ac6ca34af49706c0d7f5e/5cba22b3-b1ad-4915-8903-1b6c36ad0b93/ChatGPT+Image+Jun+20%2C+2026%2C+07_02_53+PM+%281%29.png)






















